Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study
Background Most patients with endometrial cancer with localized disease are effectively treated and survive for a long time. The primary treatment is hysterectomy, to which surgical staging procedures may be added to assess the need for adjuvant therapy. Longitudinal data on patient-reported outcome...
Saved in:
Published in | American journal of obstetrics and gynecology |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | Norwegian |
Published |
2021
|
Online Access | Get full text |
Cover
Loading…
Abstract | Background Most patients with endometrial cancer with localized disease are effectively treated and survive for a long time. The primary treatment is hysterectomy, to which surgical staging procedures may be added to assess the need for adjuvant therapy. Longitudinal data on patient-reported outcomes comparing different levels of primary treatment are lacking, especially when adjuvant radiotherapy is omitted. Objective We assessed the impact of lymphadenectomy and adjuvant chemotherapy on patient-reported symptoms, function, and quality of life. We hypothesized that these treatment modalities would substantially affect patient-reported outcomes at follow-up. Study Design We prospectively included patients with endometrial cancer enrolled in the ongoing MoMaTEC2 study (ClinicalTrials.gov Identifier: NCT02543710). Patients were asked to complete the patient-reported outcome questionnaires European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire EN24 preoperatively and at 1 and 2 years of follow-up. Functional domains and symptoms were analyzed for the whole cohort and by treatment received. To assess the effect of the individual treatment modifications, we used mixed regression models. Results Baseline data were available for 448 patients. Of these patients, 339 and 219 had reached 1-year follow-up and 2-year follow-up, respectively. Treatment included hysterectomy (plus bilateral salpingo-oophorectomy) alone (n=177), hysterectomy and lymph node staging without adjuvant therapy (n=133), or adjuvant chemotherapy irrespective of staging procedure (n=138). Overall, patients reported improved global health status and quality of life (+9 units; P<.001), increased emotional and social functioning, and increased sexual interest and activity (P<.001 for all) from baseline to year 1, and these outcomes remained stable at year 2. Means of functional scales and quality of life were similar to age- and sex-weighted reference cohorts. Mean tingling and numbness and lymphedema increased after treatment. The group who received adjuvant chemotherapy had a larger mean reduction in physical functioning (−6 vs +2; P=.002) at year 1, more neuropathy (+30 vs +5; P<.001; year 1) at years 1 and 2, and more lymphedema at year 1 (+11 vs +2; P=.007) than the group treated with hysterectomy and salpingo-oophorectomy only. In patients not receiving adjuvant chemotherapy, patient-reported outcomes were similar regardless of lymph node staging procedures. Adjuvant chemotherapy independently increased fatigue, lymphedema, and neuropathy in mixed regression models. Conclusion Patients with endometrial cancer receiving adjuvant chemotherapy reported significantly reduced functioning and more symptoms up to 2 years after treatment. For patients treated by surgery alone, surgical staging did not seem to affect the quality of life or symptoms to a measurable degree at follow-up. Therefore, subjecting patients to lymph node removal to tailor adjuvant therapy seems justified from the patient’s viewpoint; however, efforts should increase to find alternatives to traditional chemotherapy. |
---|---|
AbstractList | Background Most patients with endometrial cancer with localized disease are effectively treated and survive for a long time. The primary treatment is hysterectomy, to which surgical staging procedures may be added to assess the need for adjuvant therapy. Longitudinal data on patient-reported outcomes comparing different levels of primary treatment are lacking, especially when adjuvant radiotherapy is omitted. Objective We assessed the impact of lymphadenectomy and adjuvant chemotherapy on patient-reported symptoms, function, and quality of life. We hypothesized that these treatment modalities would substantially affect patient-reported outcomes at follow-up. Study Design We prospectively included patients with endometrial cancer enrolled in the ongoing MoMaTEC2 study (ClinicalTrials.gov Identifier: NCT02543710). Patients were asked to complete the patient-reported outcome questionnaires European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire EN24 preoperatively and at 1 and 2 years of follow-up. Functional domains and symptoms were analyzed for the whole cohort and by treatment received. To assess the effect of the individual treatment modifications, we used mixed regression models. Results Baseline data were available for 448 patients. Of these patients, 339 and 219 had reached 1-year follow-up and 2-year follow-up, respectively. Treatment included hysterectomy (plus bilateral salpingo-oophorectomy) alone (n=177), hysterectomy and lymph node staging without adjuvant therapy (n=133), or adjuvant chemotherapy irrespective of staging procedure (n=138). Overall, patients reported improved global health status and quality of life (+9 units; P<.001), increased emotional and social functioning, and increased sexual interest and activity (P<.001 for all) from baseline to year 1, and these outcomes remained stable at year 2. Means of functional scales and quality of life were similar to age- and sex-weighted reference cohorts. Mean tingling and numbness and lymphedema increased after treatment. The group who received adjuvant chemotherapy had a larger mean reduction in physical functioning (−6 vs +2; P=.002) at year 1, more neuropathy (+30 vs +5; P<.001; year 1) at years 1 and 2, and more lymphedema at year 1 (+11 vs +2; P=.007) than the group treated with hysterectomy and salpingo-oophorectomy only. In patients not receiving adjuvant chemotherapy, patient-reported outcomes were similar regardless of lymph node staging procedures. Adjuvant chemotherapy independently increased fatigue, lymphedema, and neuropathy in mixed regression models. Conclusion Patients with endometrial cancer receiving adjuvant chemotherapy reported significantly reduced functioning and more symptoms up to 2 years after treatment. For patients treated by surgery alone, surgical staging did not seem to affect the quality of life or symptoms to a measurable degree at follow-up. Therefore, subjecting patients to lymph node removal to tailor adjuvant therapy seems justified from the patient’s viewpoint; however, efforts should increase to find alternatives to traditional chemotherapy. |
Author | Werner, Henrica Maria Johanna Trovik, Jone Vistad, Ingvild Rege, Astri Sævik-Lode, Margaret Woie, Kathrine Ellstrøm Engh, Marie Andreasen, Stine Nordskar, Nina Jebens Barbero, Mark L Berge Nilsen, Elisabeth Krakstad, Camilla Forsse, David Erik Haldorsen, Ingfrid S |
Author_xml | – sequence: 1 fullname: Forsse, David Erik – sequence: 2 fullname: Barbero, Mark L – sequence: 3 fullname: Werner, Henrica Maria Johanna – sequence: 4 fullname: Woie, Kathrine – sequence: 5 fullname: Nordskar, Nina Jebens – sequence: 6 fullname: Berge Nilsen, Elisabeth – sequence: 7 fullname: Ellstrøm Engh, Marie – sequence: 8 fullname: Vistad, Ingvild – sequence: 9 fullname: Rege, Astri – sequence: 10 fullname: Sævik-Lode, Margaret – sequence: 11 fullname: Andreasen, Stine – sequence: 12 fullname: Haldorsen, Ingfrid S – sequence: 13 fullname: Trovik, Jone – sequence: 14 fullname: Krakstad, Camilla |
BookMark | eNqFjUFKxEAQRRsZwYx6BusCgUzGmUnciuLCpftQdFeSHpKqprs6kMN4VyO4d_X_h897e7NjYboxxaFqL-W5OTc7U1RVVZft8dLcmX1K199Zt3Vhvj-FB6_ZecYJqO_JagLpAd01L8gKdqRZdKSIYQVkB9M6hxFYHEFSHDwPIAwB1RNrGSlIVHIgWa3MlMAzELutavSbwyJbipByXPwiMb0AQoiSwmb2C4GVcQNs6OzWB3Pb45To8S_vzdP729frR2mjT-q5Y4nYHarmVHdN-9yejv8_fgA8K1zU |
ContentType | Journal Article |
Copyright | info:eu-repo/semantics/openAccess |
Copyright_xml | – notice: info:eu-repo/semantics/openAccess |
DBID | 3HK |
DatabaseName | NORA - Norwegian Open Research Archives |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-6868 |
ExternalDocumentID | 10852_89495 |
GroupedDBID | --- --K --M -ET .1- .55 .FO .GJ .XZ .~1 08R 0R~ 1B1 1CY 1P~ 1~. 1~5 23M 2KS 354 3HK 3O- 4.4 457 4CK 4G. 53G 5GY 5RE 5VS 6J9 7-5 85S 8F7 8P~ AACTN AAEDT AAIAV AAIKC AAIKJ AAKOC AALMO AALRI AAMNW AAOAW AAPBV AAQFI AAQQT AAQXK AAUGY AAWTL AAXUO AAYJJ ABBQC ABFNM ABFRF ABLVK ABMAC ABMZM ABOCM ABPIF ABPMR ABQIS ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADMUD ADOJD AEBSH AEFWE AEKER AENEX AEVXI AFCHL AFCTW AFDAS AFFNX AFKWA AFRHN AFTJW AFUVZ AFXIZ AGHFR AGNAY AGUBO AGYEJ AI. AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK AKALU ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 C5W CAG COF CS3 EBS EFJIC EJD EO8 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q G8K GBLVA HZ~ IH2 IHE J1W K-O KOM LCYCR M41 MO0 N4W N9A NCXOZ NEJ NQ- O-L O9- OAUVE OBH OCB OGEVE OHH OHT OMK OQ. OVD P-8 P-9 P2P PC. PH~ Q38 R2- RIG ROL RPZ RXW SDF SEL SES SEW SJN SPCBC SSH SSZ T5K TAE TEORI TWZ UDS UGJ UHB UHS UHU UKR UNMZH UV1 VH1 VVN WH7 WOQ WOW X6Y X7M XFW YFH YOC YYQ YZZ Z5R ZA5 ZGI ZXP ZY1 ~G- ~H1 |
ID | FETCH-cristin_nora_10852_894953 |
ISSN | 0002-9378 |
IngestDate | Sat Apr 29 05:43:38 EDT 2023 |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | Norwegian |
LinkModel | OpenURL |
MergedId | FETCHMERGED-cristin_nora_10852_894953 |
OpenAccessLink | http://hdl.handle.net/10852/89495 |
ParticipantIDs | cristin_nora_10852_89495 |
PublicationCentury | 2000 |
PublicationDate | 2021 |
PublicationDateYYYYMMDD | 2021-01-01 |
PublicationDate_xml | – year: 2021 text: 2021 |
PublicationDecade | 2020 |
PublicationTitle | American journal of obstetrics and gynecology |
PublicationYear | 2021 |
SSID | ssj0002292 |
Score | 4.7859263 |
Snippet | Background Most patients with endometrial cancer with localized disease are effectively treated and survive for a long time. The primary treatment is... |
SourceID | cristin |
SourceType | Open Access Repository |
Title | Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study |
URI | http://hdl.handle.net/10852/89495 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NS8NAEF1KD-JF_KR-z8FbiDSJTVtvIkoR66mit7LdJFLRXUgTQQ_e_Bn-V2eyu-kqCuolhASSNu8xO7v73gxjB-20222LLPOzQHAfo1_k8zAUftYVURwlAY8S8jsPr-LB9dHFbee20XhzVEtlMTkUL9_6Sv6DKl5DXMkl-wdk64fiBTxHfPGICOPxVxhfKuo2VCZVZytHmcGT-xIz5MJDRB6NxUrXWXp4RvQ8qRIqLGsaFNXFVX29gYApqCoL_L2VVstLZYKnuruHII7k3qzEAPOk8pm2SmMQtoZNjxru5oVTtdZWuLU7Q06pCjVBilGHAF0n-u5ZpuLTKv85vkI3fqyk9xS058YinpPWxfqNvHoR-ybNjYmHDBj4Tro_5SQ65lLORyGld2ZITpJbcYFZ_tBuaieYY3alw3eq43e73_XjXtybD292S__LqFdrEcl-EY57fZwpUg2E9hFFy8PXuVAoDPuhnUTR63CmJKoALJ1MZLTMlswUAk40H1ZYQ6pVtjA0Iok19u7SAgwtQGVgaQEuLQA_PVS0AKIFGFqAkvCVFmBpAVMJDi1A0wJqWhwDB4cUoEkBFSnW2f752eh04Jt_N5YYhMbO54k2WFMqmbYYiECIgDqdJZiOhr10EncCTkoNakcgws4ma_30lK2fb22zRYJYr3DtsGaRl-ku5nzFZK-C5ANsNWy_ |
link.rule.ids | 230,315,786,790,891,4043 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Longitudinal+effects+of+adjuvant+chemotherapy+and+lymph+node+staging+on+patient-reported+outcomes+in+endometrial+cancer+survivors%3A+a+prospective+cohort+study&rft.jtitle=American+journal+of+obstetrics+and+gynecology&rft.au=Forsse%2C+David+Erik&rft.au=Barbero%2C+Mark+L&rft.au=Werner%2C+Henrica+Maria+Johanna&rft.au=Woie%2C+Kathrine&rft.date=2021&rft.issn=0002-9378&rft.eissn=1097-6868&rft.externalDBID=n%2Fa&rft.externalDocID=10852_89495 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9378&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9378&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9378&client=summon |